Conivaptan-d4 – 1 mg

Brand:
Cayman
CAS:
1129433-63-1
Storage:
-20
UN-No:
Non-Hazardous - /

Conivaptan-d4 is intended for use as an internal standard for the quantification of conivaptan (Item No. 23728) by GC- or LC-MS. Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V1A and V2 (Kis = 0.48 and 3.04 nM for rat liver V1A and kidney V2, respectively).{38430} It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki = 44 nM) but has no effect on AVP binding to anterior pituitary V1B receptors at concentrations up to 100 μM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs) in vitro and the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.{38431}  

 

Available on backorder

SKU: 26455 - 1 mg Category:

Description

An internal standard for the quantification of conivaptan by GC- or LC-MS


Formal name: N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl-d4]-[1,1′-biphenyl]-2-carboxamide

Synonyms: 

Molecular weight: 502.6

CAS: 1129433-63-1

Purity: ≥99% deuterated forms (d1-d4)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Cardiovascular Diseases|Stroke||Research Area|Cardiovascular System|Kidney & Renal Disease||Research Area|Cardiovascular System|Vasculature|Smooth Muscle Cells||Research Area|Neuroscience|Neuroprotection|Ischemia